Stock Price & Analysis

Based on the analysis of TECH stock, it is recommended to hold as the stock is currently undervalued with a price target of $79.00 and shows potential for recovery.

Price Prediction for TECH Stock in 2025

Based on current trends and analysis, TECH stock is predicted to reach $65-$67 in the short term, driven by its recent product expansion and strong market position. However, it may face resistance due to sector-wide pressures and a recent price target adjustment by Citi to $70. Long-term growth is expected to stabilize around $70 as the company continues to innovate in spatial biology research.

The S1 support level for TECH Stock is $57.81 ,The R1 resistant level for TECH Stock is $64.15.

As of the end of day on 2025-03-14, the price of TECH Stock was $59.8.

The target price for TECH Stock according to analyst rating is 83.67, with the highest price target at 95.00 and the lowest at 68.00. Analysts have a Moderate Buy rating on TECH Stock overall.

The market cap of TECH is $9.5B.

Analysis and Insights

To determine whether TECH is overvalued, we'll analyze Nvidia (NVDA) as a representative of the TECH sector, focusing on key metrics and market trends.

Valuation Analysis:

Nvidia's valuation metrics indicate a premium relative to its peers. The stock currently trades at a price-to-sales (P/S) ratio of 21.6, significantly higher than historical averages, suggesting potential overvaluation.

Market Sentiment and Analyst Views:

Recent market sentiment has been mixed, with some analysts expressing optimism about Nvidia's dominance in AI, while others caution against high valuations and potential market risks.

Technical Trends:

The stock has shown volatility, with recent sell-offs and rebound potential. Technical indicators suggest a potential reversal, but the stock remains in a corrective phase.

Conclusion:

Nvidia appears overvalued based on its high P/S ratio and recent sell-offs. However, its strong position in AI and growth prospects could justify the premium. Investors should approach with caution, considering both the short-term risks and long-term potential.

Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

The price prediction for TECH stock by 2030 is expected to range between $70 and $85, with a mid-point target of $78. This forecast considers the stock's current price of $63.24, positive Q2 earnings, and analyst upgrades, offset by market overvaluation concerns.

TECH has a total of 3050 employees.